Last reviewed · How we verify
Lactose tablets
Lactose tablets, developed by the University of Dundee, are currently marketed but lack a defined primary indication or revenue data. The key composition patent is set to expire in 2028, which may provide a temporary barrier to generic competition. The absence of detailed clinical trial results and identified competitors poses a significant risk to assessing the drug's market potential and competitive landscape.
At a glance
| Generic name | Lactose tablets |
|---|---|
| Sponsor | University of Dundee |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis (PHASE4)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (PHASE3)
- Dual Orexin Antagonism and Emotion and Affective Processing Study (PHASE4)
- Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
- Phase I Trial of Defactinib and VS-6766. (PHASE1)
- Cabozantinib for Patients With Recurrent or Progressive Meningioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactose tablets CI brief — competitive landscape report
- Lactose tablets updates RSS · CI watch RSS
- University of Dundee portfolio CI